ArticleResearch square2026
Clinical and genomic predictors of sipuleucel-T outcomes in men with metastatic androgen pathway modulator resistant prostate cancer.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundSurvival outcomes following sipuleucel-T in men with metastatic androgen pathway modulator resistant prostate cancer (mAPMR) are variable. Genomic alterations influencing immune response and tumor proliferation may explain outcome heterogeneity. We sought to identify clinical and genomic correlates of survival following sipuleucel-T.
methodsWe conducted a single-center retrospective study of men with mAPMR and accessible tumor genomic data who received sipuleucel-T at the Duke Cancer Institute (2014-2024). The primary objective was to associate clinical factors and somatic genomic alterations with overall survival (OS) using multivariable Cox models.
resultsAmong 429 men treated with sipuleucel-T, 185 (43%) had molecular data (tumor tissue 43%, cfDNA 57%). Median age was 70; most were ECOG 0 (60%) and White (85%) or Black (14%). Frequent alterations included TP53 (48%), AR amplification (27%), PTEN loss (20%), and MYC gain (10%). Median OS and progression-free survival (PFS) were 44 and 3.6 months, respectively. MYC gain was the strongest independent genomic predictor of poorer OS. On multivariable analysis, predictors of poorer OS included ≥ 10 bone metastases (HR 42.4, 95% CI 10.3-175, p < 0.001), MYC gain (HR 7.96, 95% CI 2.88-22.0, p < 0.001), older age (HR 1.05, 95% CI 1.01-1.09, p = 0.017), TMPRSS2 wild type vs. mutation (HR
conclusionsMYC gain is strongly associated with poorer OS following sipuleucel-T. Aggressive tumor biology, immune evasion, and advanced disease state may underlie these inferior outcomes; alternative therapies should be considered in MYC-amplified mAPMR. Multicenter validation is planned to further enhance patient selection for sipuleucel-T.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.